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Abstract: MVA is an attenuated vector that still retains immunomodulatory genes. We have
previously reported its optimization after deleting the C12L gene, coding for the IL-18 binding-protein.
Here, we analyzed the immunogenicity of MVA vectors harboring the simultaneous deletion of
A44L, related to steroid synthesis and A46R, a TLR-signaling inhibitor (MVA∆A44L-A46R); or also
including a deletion of C12L (MVA∆C12L/∆A44L-A46R). The absence of biological activities of
the deleted genes in the MVA vectors was demonstrated. Adaptive T-cell responses against
VACV epitopes, evaluated in spleen and draining lymph-nodes of C57Bl/6 mice at acute/memory
phases, were of higher magnitude in those animals that received deleted MVAs compared to
MVAwt. MVA∆C12L/∆A44L-A46R generated cellular specific memory responses of higher quality
characterized by bifunctionality (CD107a/b+/IFN-γ+) and proliferation capacity. Deletion of
selected genes from MVA generated innate immune responses with higher levels of determining
cytokines related to T-cell response generation, such as IL-12, IFN-γ, as well as IL-1β and IFN-β.
This study describes for the first time that simultaneous deletion of the A44L, A46R and C12L
genes from MVA improved its immunogenicity by enhancing the host adaptive and innate immune
responses, suggesting that this approach comprises an appropriate strategy to increase the MVA
vaccine potential.
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1. Introduction
Modified Vaccinia Ankara Virus (MVA) was originally developed as a vaccine for smallpox
in primary chicken embryo fibroblasts (CEF) through serial passages of Chorioallantois Vaccinia
virus Ankara (CVA). After this process, MVA lost its capacity to replicate in vivo in mammalian
cells, restricting its productive replication to certain permissive cell-lines, such as BHK-21 [1–3].
A comparison of genomic sequences of CVA and MVA [4,5] indicated that, in addition to six large
deletions, MVA presents mutations in more than 60% of the open reading frames (ORFs), however
the mutations responsible of its in vivo attenuation remain unknown [6]. The MVA immunogenic
capacity, as well as its high level of safety, and the feasibility to incorporate large foreign gene
inserts has converted it to an attractive candidate for clinical vaccine development strategies against
different infectious diseases such as HIV/AIDS, Malaria, Hepatitis B and C, Tuberculosis, and also
smallpox [7–16]. Despite the loss of several immunomodulatory genes, MVA still preserves genes
directed to evade the host immune response [17], the directed deletion from the MVA genome of these
genes can constitute a strategy to improve its immunogenicity. This proof of concept was demonstrated
previously, e.g., after deleting the gene encoding an interleukin-1β binding-protein [18], and also after
the removal of the A41L gene encoding for a chemokine binding-protein [19]. Moreover, our group
described that the deletion of the C12L gene from MVA genome, encoding for the interleukin-18 (IL-18)
binding-protein generated a significant improvement in the immunogenicity of the vector leading
to an increase in the magnitude and quality of specific cellular responses against Vaccinia (VACV)
antigens and, more importantly, to HIV antigens [20]. Moreover, many other studies performed by
other groups also demonstrated better levels of immunogenicity against recombinant antigens (mainly
HIV proteins) expressed from the MVA specific deleted mutants [21–24].
The A46R VACV-gene still present in the MVA genome encodes for a protein that inhibits
numerous TLR-signaling pathways through its binding to TIR domains [25] disrupting the association
of adaptor proteins, such as MyD88, Mal/TIRAP, TRAM, and TRIF, consequently, prevents the
interaction with the receptor and avoids the activation of NF-κB, IRF3/IRF7 and MAP-kinase
pathways [26], thus contributing to the evasion of the immune response elicited by the host [27–29].
A44L is another VACV-gene present in the MVA genome encoding a 3β-hydroxysteroid-
dehydrogenase/∆5-∆4 isomerase (3β-HSD), which participates in steroid hormone metabolism,
catalyzing reactions like the conversion of pregnenolone into progesterone [30], among others.
Some steroid hormones are glucocorticoids considered to be potent immunosuppressive and
anti-inflammatory agents that modulate cytokine production, and the migration and cytotoxicity
of immune cells [31].
Previous reports have demonstrated that deletion of A46R from the VACV genome (Western
Reserve strain, WR) generated an attenuated intranasal infection in a murine model [26] and that after
its deletion from the New York Vaccinia Virus (NYVAC) genome backbone, immune responses against
recombinant HIV antigens were improved [32]. However, previous reports describing its deletion
from the MVA genome indicated the failure to improve vector immunogenicity [33,34].
In relation to the A44L gene, previous data showed that, in the WR strain, it contributes to virulence
after intranasal [35,36] or intradermal infection of mice [37], and also that its deletion produced an
increase in the inflammatory response and cytotoxic T lymphocyte activities after intranasal inoculation
of mice [30]. However, previous studies described that the deletion of this gene from MVA generated
no increase in its immunogenicity [33,34].
In this study we did an in-depth characterization of the effects of simultaneous deletion of the
A46R and A44L genes from the MVA genome. For this, we deleted the A44L-A46R segment that
also includes the A45R gene. However, as the product of this last gene is an inactive superoxide
dismutase-like protein [4,38], we did not focus on the effect of A45R absence. Importantly, in contrast
with other studies, we demonstrated for each of the immunomodulatory viral genes that their removal
from the vector genome generated an ablation of their biological functions. Then, in an in vivo mouse
model, we showed that by deleting the A46R and A44L genes from MVA, in combination with the C12L
Viruses 2016, 8, 139 3 of 21
gene, improves the immunogenicity of the vector inducing an immune response of higher magnitude
and better quality in comparison with the MVAwt. Moreover, we found that the deletion of these three
viral genes produced an increase in the in vivo inflammatory innate immune responses which have an
impact on the generation of adaptive immune responses.
2. Materials and Methods
2.1. Cells and Viruses
MVA-deleted viruses were generated in primary cultures of chicken embryo fibroblasts (CEFs) as
described previously [20].
BHK-21 (ATCC CCL-10) and BSC-40 (ATCC CRL-2761) were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) and THP-1 (ATCC TIB-202) cells in RPMI-1640, both supplemented with
2 mM L-glutamine, penicillin 100 U/mL, streptomycin 0.1 mg/mL (DMEMc and RPMIc, respectively)
and complemented with 10% heat inactivated fetal bovine serum (FBS). Cells were maintained at
37 C in a 5% CO2 atmosphere. THP-1–derived macrophages were obtained by stimulating THP-1
monocytes with 50 ng/mL of phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich, St. Louis, MO,
USA) for three days.
2.2. Construction of Deleted MVAs: MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R
To construct an MVA lacking the A44L and the A46R VACV genes, A44L-gene upstream-region
and A46R-gene downstream-regions (nucleotide positions 142215–142569 and 144651–144994,
respectively, GeneBank sequence ID: U94848.1) were amplified by PCR and cloned into pBlueScript
(Stratagene) obtaining the intermediate plasmid pBS-A44L-A46R. Primers used were 157iF
51-AGAGCTCGGATAAAATCAAAATTACGGTTG-31/157iR 51-AGCGGCCGCCGAACACGGAAA
TGGCTAGA-31 and 159dF: 51-CGGATCCGATGATTCGTCTACATGTTC-31/159dR: 51 AGAATTCGCC
CACATAAATGCGTTGGAG-31. Then, the uidA gene (β-glucuronidase enzyme, GUS) under the
poxviral H6-promoter (available in our laboratory) was subcloned into pBS-A44L-A46R obtaining
p∆A44L-A46R (transference-vector). Identities of all plasmids were verified by DNA sequencing.
The p∆A44L-A46R plasmid was transfected into cells infected with the MVA-F6 isolate obtained after
582 passages in CEF cells [39] provided by G. Sutter (Paul-Ehrlich-Institut, Langen, Germany), or
with the MVA∆C12L vector [20]. MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R were wild-type
virus-free after ten or six consecutive rounds of plaque purification on CEFs in the presence of GUS
substrate (X-gluc, Inalco, San Luis Obispo, CA, USA), respectively. Purity of the selected clones was
verified by PCR, employing specific primers.
RT-PCRs
CEFs were non-infected or infected at multiplicity of infection (moi) of 1 with MVAwt,
MVA∆A44L-A46R or MVA∆C12L/∆A44L-A46R. Twenty-four hours post-infection (hpi) cells were
harvested and RNA was extracted using Trizol following the manufacturer’s instructions (MRC
Inc, Cincinnati, OH, USA). RNA samples were treated with DNaseI (Invitrogen, Vilnius, Lithuania)
and reverse-transcribed with M-MLV reverse-transcriptase (Promega, Madison, WI, USA) using
random hexamers. The A44L, A46R, C12L, and TK (thymidine-kinase) genes were amplified from
cDNA. Primers used were for A44L: 159intF 51-CTTAAAGTAGACTCCGATTC-31/159STOP51-TTATAC
ATCCGTTTCCCTG-31, for A46R: 157intF 51-GGAAATGCTTACTTTTGCTA-31/157STOP 51-TTATTC
TGATTCTTCTAGCC-31, for C12L detailed in [20] and for TK: TK1 51-TCCCCGCGGTGAA
CGGCGGACATATTC-3´/TK4 51-GGGGTACCTTATGAGCCGACGTAACA-31.
2.3. Viral Immunization Stocks
MVA viral stocks were grown in BHK-21 cells, purified by ultracentrifugation through 45%
sucrose-cushion and titrated by immunostaining using a rabbit polyclonal antibody against B5 and
A33 VACV-proteins (#V0500-11D, US Biological, Salem, MA, USA) [40].
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In Vitro Characterization of MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R Viruses
To analyze the virus growth kinetics, BHK-21 monolayers (70% confluence) were infected
(moi = 0.01) with different MVAs. For each virus and time point, cells (intracellular-virus) and
supernatants (extracellular-virus) were collected separately, frozen/thawed three times, and stored at
80 C until titration by immunostaining. Each time point was evaluated by duplicate.
2.4. THP-1 Infection and Cytokine Production Evaluation
THP-1–derived macrophages were uninfected or infected with distinct MVAs (moi = 5).
At different hours post-infection supernatant was collected and stored at 80 C for future analysis.
IL-1β was measured with a commercial kit (Biolegend, San Diego, CA, USA) following the
manufacturer’s instructions.
2.5. 3β-HSD Activity
We followed the protocol described by Moore and Smith [35] with slight modifications. Briefly,
BSC-40 cells were uninfected or infected with distinct MVAs (moi = 10), 18 h later cells were washed
and incubated for 1 h at 37 C with Buffer A [35], 0.66 mM β-nicotinamide adenine dinucleotide (NAD,
Sigma, St Louis, MO, USA) and 4 mM 5-pregnen-3β-ol-20-one (Sigma, St Louis, MO, USA). Afterwards,
cells were permeabilized with 1% saponin for 1 h at 37 C and the reaction was stopped with 1.2 N
HCl. Subsequently, we added 10 nmol of 5-pregnen-16-methylene-3β,17-diol-20-one3-acetate as an
internal control, in order to check the efficiency of the process. Extraction of steroids was performed
with ethyl acetate, subsequently evaporated, and then methanol-dissolved steroids were analyzed
by LC-MS/MS.
2.6. IL-18 Binding-Protein Bioassay
The functional assay to evaluate the effect of the absence of the C12 protein in these new deleted
vectors was performed as described previously by Falivene et al. [20] with some modifications. Briefly,
BHK-21 cells instead of CEFs, were uninfected or infected with distinct MVAs (moi = 5). Twenty-four
hours post-infection, supernatants were harvested, clarified from cell debris and viral particles, and
stored at 20 C until use. Splenocytes from C57Bl/6 instead of Balb/C mice were cultured in RPMIc
plus 10% of FBS with 200 ng/mL Concanavalin A (ConA) alone or in combination with 10 ng/mL of
murine recombinant IL-18 (rIL-18), for 24 h at 37 C. To evaluate the inhibitory action of C12 on IL-18,
the rIL-18 was pre-incubated with clarified supernatants defined before, for 1 h at room temperature.
After that, levels of IFN-γ in culture supernatants were measured by IFN-γ ELISA set, following the
manufacturer’s instructions (BD Biosciences, San Diego, CA, USA).
2.7. Immunization Protocols, Sample Collection, and Processing
SPF C57Bl/6 (H-2b) female mice, 6–8 weeks old, were purchased from the laboratories of the
School of Veterinary Sciences, University of La Plata, Buenos Aires, and housed in our animal facilities.
All experiments were carried out in accordance with recommendations in the Guide for the Care and
Use of Laboratory Animals (NIH). The protocol was approved by Committee of Care and Use of
Laboratory Animals from School of Medicine, University of Buenos Aires (Permit Number: 508/2009).
All immunizations were performed intramuscularly (i.m) in 100 µL of PBS (50 µL per leg, in the tibial
muscle), with a dose of 1  107 plaque-forming units (PFU) of the indicated virus. Seven or 45 days
after immunization, mice were sacrificed to collect samples (spleen and inguinal lymph nodes, ILNs).
Blood samples were obtained by cardiac punction from anesthetized mice and sera were obtained by
standard procedures. Splenocytes and lymphocytes from ILNs were isolated by routine methods [41].
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2.8. Analysis of Specific T-Cell Immune Responses
2.8.1. Peptides
Lyophilized VACV-specific synthetic peptides (JPT Peptide Technologies) dissolved in
dimethylsulfoxide (DMSO, Sigma-Aldrich, St Louis, MO, USA) were used at a final concentration of
2 µg/mL for ELISPOT and ELISA assays, and 4 µg/mL for flow-cytometry assays. B8R and E9L, H3L,
and L4R peptides were previously described as MHCI restricted and as MHCII restricted epitopes in
C57Bl/6 mice (CD8+ and CD4+ specific, respectively) [42].
2.8.2. Murine IFN-γ and IL-2 ELISPOT Assays
ELISPOT assays were performed using freshly isolated splenocytes and cells from ILNs as
described previously [43]. Briefly, 5 104 to 106 cells in RPMIc were plated in triplicate on nitrocellulose
96-well plates (Millipore, Billerica, MA, USA) coated with anti-mouse IFN-γ or anti-mouse IL-2
antibodies (BD Biosciences). Specific stimuli consisted in VACV-specific peptides, RPMIc with 0.08%
of DMSO (negative control) and concanavalin A (ConA 1 mg/mL, positive control). The response
was considered positive when the number of specific spots per well overcame at least two times the
average from negative control of each group.
2.8.3. Intracellular Cytokine Staining (ICS) and Proliferation Assays
Splenocytes were dispensed in 96-well U bottom plates (106 cells/well) and stimulated with B8R
(4 µg/mL) for 5 h in presence of co-stimulatory antibody anti-CD28 (1 ng/mL), brefeldin A (1 µL/mL
GolgiPlug), monensin (0.7 µL/mL GolgiStop), and monoclonal antibodies anti-CD107a-FITC and
anti-CD107b-FITC (all reagents from BD Biosciences) [44]. Negative and positive controls consisted
of cells stimulated with RPMIc plus 0.16% of DMSO, or PMA/Ionomycin (PMA 10 ng/mL plus
ionomycin 250 ng/mL, Sigma-Aldrich), respectively. Afterwards, cells were washed and stained with
a probe to distinguish between live and dead cells (Live/Dead reactive, Life Technologies, Burlington,
ON, Canada) and with surface antibodies: CD8-PerCP or CD4-PerCP, CD44-PECy7, CD62L-APC for
30 min at 4 C. After that, cells were permeabilized and fixed using Cytofix/Cytoperm kit, stained
using anti-IFN-γ-PE (all reagents from BD Biosciences) for 30 min at 4 C in the dark, washed and
acquired in a FACSCanto flow cytometer (BD Biosciences).
Proliferation assays were performed as we described previously [45,46]. After labeling with
carboxyfluorescein-succinimidyl-ester (CFSE), cells were cultured in 12-wells plates (107 cells/mL)
and stimulated with UV-inactivated VACV (2.5 µg/mL), PMA/Ionomycin (positive controls) or
with medium alone (negative controls). After four days, lymphocytes were harvested, counted, and
washed with RPMIc. Then, cells were stained for 30 min at 4 C with anti-mouse CD8-PerCP or
CD4-PerCP, CD44-PECy7, CD62L-APC (BD Biosciences) plus the viability dye, washed, and acquired
in a FACSCanto flow cytometer.
Data acquisition and analysis were performed with FACSDiva Software (BD Biosciences).
Instrument settings and fluorescence compensation were performed on each testing day using
unstained and single-stained samples. Stimulated cells stained for surface molecules and isotype
matched controls were included in each experiment.
2.8.4. T-Cell Specific Cytokine Production
Splenocytes were suspended in RPMIc, cultured as we explained in [45] and stimulated for 72 h
with the indicated peptides, ConA or RPMIc. Then, supernatants were harvested and stored at 80 C
until use. Cytokine production was evaluated using IFN-γ and IL-2 ELISA sets (BD Biosciences) or the
Th1/Th2 cytokine kit (Cytometric Bead Array, CBA, BD Biosciences), following the manufacturer's
instructions. The response was considered positive when cytokine quantities exceeded the average
values found in negative controls of each group plus 3 SD.
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2.8.5. In Vitro Cytotoxicity Assays
The in vitro cytotoxicity assay was based on Nakagawa et al. [47]. Splenocytes from MVAwt or
MVA∆C12L/∆A44L-A46R immunized mice (7 dpi) were used as effector cells (cytotoxic T-CD8+ cells).
Splenocytes from naïve C57Bl/6 mice were used as target cells. For that, target cells were stained
with 6 uM of CFSE (control target) or 16 uM (sensitive target). Sensitive target cells were pulsed with
B8R peptide (5 µg/mL) for 30 min at 37 C. For sensitive reactions, effector cells (1  105 cells) were
incubated with different amounts of sensitive target cells for 4 h at 37 C. The ratio of Effector/Target
cells was 0.5:1 to 10:1. In the same way, control target cells were incubated with effector cells, covering
the same ratio. After incubation, sensitive and control target cells at the same Effector/Target ratio
were mixed, washed with PBS and the acquisition of the cells was performed using a BD FACSCanto
flow cytometer.
2.9. Innate Immune Response Analyses
Groups of four to six C57Bl/6 mice were i.m immunized with 2  107 PFU of MVAwt or
MVA∆C12L/∆A44L-A46R (100 µL, 50 µL per leg in tibial muscle). At each time point, animals
were sacrificed and blood and ILNs were obtained by routine methods. For cytokine analysis, ILNs
of each mouse were suspended in PBS plus Protease Inhibitor and EDTA (Pierce) processed with a
homogenizer (UltraTurrax-T25 homogenizer, IKA, Staufen, Germany) and transferred immediately to
ice. Samples were centrifuged and supernatants were stored at 80 C until analyzed. Cytokines were
measured by ELISA (anti-mouse ELISA sets for IFN-γ, IL-12 and IL-1β, BD Pharmigen, San Diego,
CA, USA).
RNA extraction was performed using the TRIzol reagent and the Pure Link RNA Mini Kit
(Ambion, Burlington, ON, Canada). RNA (5 µg) was treated with DNAse I and reverse-transcribed
as we described before. Quantitative PCR was performed with a 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) using SYBR Select Master Mix (Life Technologies) and
the following primers: IFN-βF 51-GCACTGGGTGGAATGAGACT-31/IFN-βR 51-AGTGGAGAGCA
GTTGAGGACA-31, β-actinF51-TGTCCACCTTCCAGCAGATGT-31/β-actinR51-AGCTCAGTAACAG
TCCGCCTAGA-31. All samples were tested in triplicates. Amplifications consisted in a denaturation
step (95 C, 15 s) and an annealing/extension step (60 C, 1 min). IFN-β expression was normalized to
β-actin expression in arbitrary units (A.U.), and then all groups were relativized to the naïve group.
2.10. Data Analysis
Statistics were performed using the GraphPad Prism [48]. In all cases background values (negative
control) were subtracted. Statistical tests employed were specified in each assay.
3. Results
3.1. In Vitro Characterization of MVA Vectors after Deleting A44L, A46R, and C12L Genes
The removal of the A44L, A46R and C12L genes from deleted MVAs was firstly corroborated by
specific PCR (see supplemental data Figure S1).
Afterwards, in order to verify the absence of mRNA expression of the different genes,
we performed RT-PCRs with RNA extracted from CEFs previously infected with parental (MVAwt)
or the deleted viruses (MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R), using specific primers
detailed in Materials and Methods.
Figure 1a shows the amplification of A44L and A46R mRNAs (318 bp and 321 bp, respectively),
only present in MVAwt infected cells, and the amplification of C12L mRNA (363 bp), present in MVAwt
and MVA∆A44L-A46R but not in MVA∆C12L/∆A44L-A46R infected cells. Thymidine kinase mRNA
(TK, 525 bp) was used as positive control of viral mRNA amplification.
Afterwards, we analyzed the replicative efficiency of the vectors performing multiple-step growth
curves for all MVAs, corroborating that MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R did not
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differ in their growth kinetics curve from MVAwt (Figure 1b). Therefore, A44L, A46R, and C12L genes
are not essential for MVA replication in cell culture, even if they are simultaneously deleted.
In order to evaluate if the MVA vectors showed a similar capacity to infect antigen-presenting
cells, the human monocytic cell-line THP-1 was infected with the different MVAs and 24 hpi the
presence of early/late VACV proteins (B5R and A33R) was analyzed by immunofluorescence [49,50].
In Figure S1 it can be seen that all MVA vectors have similar and comparable capacities to infect THP-1
cells, showing an equivalent intracellular localization of the viral proteins.
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Figure 1. In vitro characterization of MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R. (a) RNA was
extracted from mock or infected CEFs with the different MVAs at 24 hpi (moi = 1), specific mRNAs
were assessed by RT-PCR; and (b) virus growth kinetics of MVA vectors. BHK-21 were infected with
the indicated MVA at moi = 0.01. At different hpi virus production was titrated by immunostaining.
3.2. In Vitro Analysis of the Biological Effects of Deleted Viral Genes
Once we confirmed the absence of expression of the A46R, A44L, and C12L genes from the deleted
MVAs, we considered it highly relevant to evaluate the biological impact that these deletions could
have. The biological function of A44L (equivalent to progesterone production by 3β-HSD enzyme)
was assayed as described in the methodology. In Figure 2a it can be clearly seen that in MVAwt
infected cells, progesterone levels were significantly higher than those found in MVA∆A44L-A46R or
MVA∆C12L/∆A44L-A46R infected cells, which were similar to those observed in mock-infected cells,
indicating that the viral ability to synthesize progesterone was no longer present in deleted MVAs.
In order to analyze the ability of the C12 protein to inhibit the biological activity of mouse IL-18,
we treated splenocytes from C57Bl/6 naïve mice with ConA or ConA plus rIL-18 in the presence of
supernatants from MVA infected BHK-21 cells, as explained in Materials and Methods. Twenty-four
hours later, IFN-γ was quantified in supernatants of splenocyte-cultures. Significantly higher levels of
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IFN-γ were found in splenocyte-cultures activated with ConA plus rIL-18 incubated with supernatants
from MVA∆C12L/∆A44L-A46R, in comparison to those incubated with supernatants from MVAwt or
MVA∆A44L-A46R (Figure 2b), indicating that IL-18 binding-protein was no longer present in cells
infected with MVA∆C12L/∆A44L-A46R.
Next, in order to evaluate the consequences of A46R absence, we infected THP-1 cells and
evaluated IL-1β production as explained in Materials and Methods. Since A46 has been characterized
as an antagonist of host IL-1 and TLR-signaling [26], quantifying the IL-1β secreted after activation of
these pathways, by MVA infection, might be a way to measure the biological effect of presence/absence
of A46. As it can be appreciated in Figure 2c we found significant higher levels of IL-1β in cells infected
with MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R vectors in comparison to MVAwt.
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The results described in this section indicated that in both deleted MVAs, the biological functions
of the A44L, A46R, and C12L genes (as anti-host immune response modulators) were absent at least in
the in vitro models assayed.
3.3. Modulation of Specific T-Cell Responses by MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R Vectors
After the in vitro characterization of the new deleted MVA vectors described above our next
aims were focused in the study of the effects caused by removing the selected genes from the MVA
genome on its immunogenicity potential. For this, we immunized groups of four C57Bl/6 mice
by intramuscular (i.m) route with 107 PFU of the different MVAs, and seven days post-inoculation
(dpi) the anti-viral specific cellular immune response induced was evaluated against VACV-epitopes.
Figure 3 shows the specific anti-VACV response elicited by the deleted MVAs compared to MVAwt.
We found that both deleted MVAs elicited a higher response (IFN-γ secreting-cells) in comparison
with MVAwt for both CD4+ (L4R) (p < 0.01) and CD8+ (B8R) (p < 0.001) T-cell epitopes (Figure 3a).
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Figure 3. Modulation of specific T-cell response after VACV gene deletion. Groups of four C57Bl/6 mice
were i.m immunized and 7 dpi specific T-cell responses were evaluated in spleen (a–c) and ILNs (d).
Magnitude of the response was measured by IFN-γ (a,d) and IL-2 (c) ELISPOT assays. Specific cytokine
production in splenocyte-culture supernatants was evaluated by ELISA (b, lef panel) or CBA (b, right
panel) after stimulation with indicated VACV-peptides. Data are expressed as mean + SD of triplicate
(a–d) or dupl cate (b) determinations, and are presentative of thre independent experiments.
Statistical analysis performed by one-way ANOVA and Bonf rroni’s post-test. Significant diffe nc s:
* p < 0.05, ** p < 0.01, *** p < 0.001. SFU: Spot-forming unit.
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In concordance, we also observed a significant increase in IL-2 secreting-cells against E9L (CD4+
epitope) (p < 0.05) and B8R (CD8+ epitope) peptides (p < 0.001 MVA∆A44L-A46R vs. MVAwt; p < 0.01
MVA∆C12L/∆A44L-A46R vs. MVAwt) (Figure 3c). Even more, analysis of cytokine production by
splenocytes of the distinct groups, after stimulation with specific VACV-peptides, showed that cells
from mice immunized with MVA∆A44L-A46R or MVA∆C12L/∆A44L-A46R produced 1.5 or up to
2-fold higher levels of IFN-γ than MVAwt (p < 0.05 and p < 0.01 respectively), and a tendency to secrete
higher TNF-α amounts against the different peptides (Figure 3b).
Considering the importance that draining lymph nodes (LNs) to the site of inoculation have in
the final outcome of the immune response [51] we also analyzed T-cell responses in inguinal LNs
(ILNs) (Figure 3d). We found that both deleted MVAs elicited a higher specific response against
CD4+ and CD8+ VACV-peptides compared to MVAwt. Additionally, the response generated by
MVA∆A44L-A46R was significantly higher than MVA∆C12L/∆A44L-A46R (p < 0.001 for B8R and
E9L). These results are in line with those observed in spleen and both indicated that specific T-cell
responses against VACV at 7 dpi were increased in mice immunized with deleted MVAs in comparison
to mice that received MVAwt.
3.4. At Later Times Post-Immunization Deleted MVAs Still Induced Higher Specific T-Cellular Responses
The specific memory cells induced after vaccination are essential players in the host defense after
the reintroduction of a pathogen antigen. To evaluate this, immune responses were studied 45 dpi in
mice immunized with the different MVAs in spleen (Figure 4a,b,d) and ILNs (Figure 4c).
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Both deleted MVAs induced higher magnitudes of anti-VACV IFN-γ secreting-cells than MVAwt
(Figure 4a,c). Importantly, MVA∆C12L/∆A44L-A46R elicited higher numbers of IL-2 secreting CD4+
and CD8+ T-cells than MVAwt (Figure 4b). This pattern of responses were corroborated by quantifying
IFN-γ, IL-2, and TNF-α in supernatants of splenocytes from different mice groups re-stimulated with
VACV-peptides (Figure 4d), where differences between MVAwt and MVA∆C12L/∆A44L-A46R were
even amplified.
It must be mentioned that we had also quantified IL-4 and IL-5 (Th2 cytokines) in supernatants of
splenocytes re-stimulated with the different VACV-peptides but, in all cases, cytokines levels were
under the limit of detection of the technique employed. Additionally, we analyzed antibody responses
induced by deleted MVAs, by quantifying IgG levels in serum from immunized mice. Although we
found slight differences when pooled serum samples were analyzed, in individual sera we did not
find significant increases in antibody responses in animals immunized with deleted MVAs, at least for
antibodies directed against surface VACV-epitopes (see supplemental data Figure S2).
3.5. MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R Vectors Improved the Quality of Memory
T-Cell Responses
Subsequently, we evaluated the quality of the memory CD8+T-cell responses induced analyzing
the bi-functionality of the CD8+T-cells in relation to their dual capacity to degranulate (measured
as CD107a/b+ cells) and produce IFN-γ in splenocytes stimulated with B8R. Figure 5a shows the
percentage of B8R specific CD107a/b+/IFNγ+ CD8+ T-cells that, for the MVA∆C12L/∆A44L-A46R
vector, was over two-fold higher compared to MVAwt (p < 0.05).
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Figure 5. Modulation of specific responses in memory T-cell subpopulations. (a) Forty five days after
immunization, splenocytes from immunized mice, were stimulated with B8R peptide. Percentage of
double-positive (CD107a/b+/IFN-γ+) CD8+T-cells was analyzed by flow-cytometry. (b) Distribution of
memory-subpopulations among bifunctional B8R-specific T-cells, classified as follows: “early-memory
or T stem-cells memory” (TSCM; CD44L/CD62L+), T central memory (TCM; CD44+/CD62L+),
T effector memory (TEM; CD44+/CD62L), and T terminal effector memory (TTEM; CD44/CD62L).
Data are representative of three independent experiments. Statistical analysis performed by one-way
ANOVA and Bonferroni’s post-test. Significant differences: * p < 0.05, *** p < 0.001.
We also analyzed the distribution and modulation of memory subpopulations involved, which
were classified according to the combination of CD44 (extracellular matrix receptor, upregulated
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after T-cell activation) and CD62L (L-selectin, homing to LNs) markers as follows: “early-memory or
T stem-cells memory” (TSCM; CD44L/CD62L+) [52,53], T central memory (TCM; CD44+/CD62L+),
T effector memory (TEM; CD44+/CD62L), and T terminal effector memory (TTEM; CD44/CD62L).
Figure 5b shows that bi-functional CD8+ T-cells (CD107a/b+/IFN-γ+) were, as expected, nearly only
present inside the TEM subpopulation, which showed significant increase of MVA∆A44L-A46R and
MVA∆C12L/∆A44L-A46R vs. MVAwt (p < 0.001).
We also evaluated the specific proliferative potential of T-cells with CFSE-based proliferation
assays as detailed in Materials and Methods. We found significant higher proliferation levels of
anti-VACV T-cells (in CD4+ and CD8+ T-cells) in mice immunized with MVA∆C12L/∆A44L-A46R
(Figure 6a). When we analyzed the memory subpopulations implicated in the specific proliferation
observed (Figure 6b,c), the higher differences between MVA∆C12L/∆A44L-A46R vs. MVAwt and
MVA∆A44L-A46R were found in the TSCM (p < 0.001 and p < 0.01, respectively), TCM (p < 0.001 and
p < 0.01, respectively) and TEM (p < 0.05) subpopulations inside the CD4+ T-cell compartment, and in
the TCM (p < 0.01 and p < 0.001, respectively) and TEM (p < 0.05 vs. MVAwt) within CD8+ T-cells.
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with UV-inactivated VACV an stained with CD4 or CD8, CD44 and CD62L. Percentage of specific
proliferating CFSElow T-cells was determined by flow-cytometry. Cells were classified in four memory
subpopulations (as detailed in Figure 5b), corresponding to CD4+ (b) or CD8+ (c) T-cells. Data are
representative of three independent experiments. Statistical analysis performed by one-way ANOVA
and Bonferroni’s post-test. Significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001.
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Finally after the results described above we considered relevant to evaluate the functionality of the
CD8+ T-cell responses generated, analyzing the specific killing capacity of T-cells in mice immunized
with MVAwt in comparison with MVA∆C12L/∆A44L-A46R. We performed an in vitro cytotoxicity
assay, evaluating specific lysis against target cells pulsed with B8R peptide as described in Materials
a d Methods (Figure 7). It can be seen that cells from MVA∆C12L/∆A44L-A46R immunized mice
showed significant higher cytoxicity capacity compared to cells from MVAwt immunized mice (p < 0.01)
(at a relation effector:target cells of 10:1), indicating that CD8+ T-cells from MVA∆C12L/∆A44L-A46R
immunized mice showed a higher functionality compare to those from MVAwt.
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with MVA∆C12L/∆A44L-A46R vs. MVAw (although not significant). Even more we served
hereas t e wt group only t o out of five ice sho e a 10-f l i r i l ti
fo r o t of six ice reached this increment in the MVA∆C12L/ , t o
of t e overca e the naïve group for more than 20-fold.
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with 2  107 PFU of MVAwt (black) or MVA∆C12/∆A44L-A46R (white) and at indicated hours
post-inoculation (hpi) were sacrificed and samples processed as explained in Materials and Methods.
Pro-inflammatory mediators were quantified in homogenates of ILNs (a) and serum (b) by ELISA. Lines
represent median values; dots, individual mice and dotted line, naïve median. (c) At six and 16 hpi,
six mice per group were sacrificed and RNA was extracted from ILNs. IFN-β mRNA was quantified
by qPCR (normalized to β-actin) and relativized to naïve mice group (dotted line). Mann-Whitney
test for statistical analysis (* p < 0.05, ** p < 0.01) was performed. Data are representative of two
independent experiments.
4. Discussion
Due to the relevance that MVA vectors currently have, there is a substantial need to improve the
vector immunogenicity potential as many MVA-based vaccines are presently being developed for use
against a number of prominent infectious diseases including AIDS, Malari , and Tuberculosi , as well
as human cancers [56]. Earlier studies demo strated that it is feasible to impr ve the immunogenicity
of MVA and generate be ter immune responses after deletion of specific viral-genes with func ions
related to evasion of t e host immune responses [20–24]. In the pr sent study, we have g nerated and
characterized an MVA vector involving the deletion of the A44L nd A46R genes (MVA∆A44L-A46R),
and considering that the C12L and A46R gene products have inter-related functions, we also constructed
another MVA including the deletion of this third gene too (MVA∆C12L/∆A44L-A46R).
It must be noticed that due to the strategy used in the deletion of the A44L and A46R genes,
the A45R gene located between both genes was also eliminated. However, the product of this last
gene has been previously described as an inactive superoxide dismutase-like protein carrying a
deletion of 12 nucleotides [4,38]; therefore, taking this into account we discarded any possible effect
on MVA due to the absence of the A45R gene. A significant point addressed in this study was to
demonstrate that the absence of selected VACV genes resulted in a lack or at least significant decrease
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in the specific biological function associated with evasion of the host immune response. For this, we
evaluated the effect of A46 absence by quantifying key inflammation markers produced after THP-1
infection. Previous studies have demonstrated that production of a mature IL-1β after MVA infection
requires a crosstalk between TLR2-MyD88 and NALP3 inflammasome [57]. Therefore, considering
that A46 interacts with MyD88 [25], the finding of a rapid increase in IL-1β in supernatants infected
with MVA∆A44L-A46R or MVA∆C12L/∆A44L-A46R vectors compared to MVAwt, was indicative
of absence of the A46 functionality in these MVAs. In relation to the A44 biological function, to our
concern, and except only for one report in which it has been described the 3β-HSD activity for many
Vaccinia strains including MVA [36], this is the first report in which the presence of the enzyme activity
has been demonstrated in the MVAwt as well as its absence after deleting the A44L gene. Regarding
the C12L biological activity, we demonstrated it in the MVA∆C12L/∆A44L-A46R, as we previously
did with the MVA∆C12L vector [20], with significant increase of IFN-γ secretion in the bioassay after
the removal of this gene.
Immunogenicity studies showed that CD8+ and CD4+ T-cell responses against VACV epitopes
resulted in significant increase at 7 dpi. Importantly, during the memory phase (45 dpi), lymphocytes
from animals immunized with deleted MVAs also showed anti-VACV cellular responses of higher
magnitude compared to MVAwt (for IFN-γ, IL-2 and TNF-α production). The analysis of the cellular
response quality in terms of the capacity of the CD8+ T-cells to simultaneously degranulate (CD107a/b)
and secrete IFN-γ, showed that MVA∆C12L/∆A44L-A46R generated higher levels of B8R specific
CD107a/b+/IFNγ+ CD8+T-cells in relation to MVAwt. Importantly, this T-cell bi-functionality was
previously associated with improved viral suppression activities of CD8+ T-cells [58]. A desirable
property for a vaccine vector is the induction of memory T-cells with proliferative potential. Notably,
we detected significantly higher proliferation levels of anti-VACV T-cells (both CD4+ and CD8+ T-cells)
after immunization with MVA∆C12L/∆A44L-A46R. It is important to remark, that we also found
higher cytotoxicity capacity in splenocytes of mice immunized by this vector in comparison to MVAwt.
Previous studies have analyzed the immunomodulatory characteristics of the A46R gene, first
defining that A46 impairs TLR-signaling by targeting the TIR domain of MyD88, Mal, TRIF and TRAM
adaptors, disrupting the interaction with the receptor and consequently diminishing the production of
pro-inflammatory cytokines as well as type I IFNs [25,26]. Moreover, it has also been shown that A46
contributes to virulence in VACV infections since the VACV A46R deletion mutant was attenuated in a
murine intranasal model [26]. However, data analyzing the consequences of its deletion on poxvirus
vaccine immunogenicity are somehow contradictory. One study [32] showed that deleting A46R
from NYVAC, increased the inflammatory cytokine response in infected human macrophages, and
also improved antigen immunogenicity after DNA-NYVAC vaccination. However, other authors
that employed the MVA-BAC system for gene deletion reported that absence of the A46R or A44L
genes did not generate an improvement in T-cell responses against epitopes of the vector [34]. More
recently, the same authors reported that cluster gene deletion from MVA (including deletion of B15R,
A46R, A44L, among others) also failed to improve acute or memory CD8+ T-cell frequencies against
any antigen tested [33]. Different methodological factors may account for these discrepancies, like
the procedures for the generation of the deleted MVAs, inoculation routes and viral doses applied.
However, undoubtedly important features to be evaluated in order to determine if a viral gene deletion
generates improvements in vector immunogenicity are the verification that the attributed biological
function of the gene is no longer present and an in vivo analysis of the innate responses induced by
the new modified vector. Both issues were directly demonstrated in our study for the three genes
selected (A46R, A44L, and C12L) and one of them (innate responses) was indirectly corroborated by
Perdiguero et al. [32]. However, none of the two previous studies involving MVA-BAC vectors that
include deletions of the A44L, A46R, and C12L genes [33,34] showed any results demonstrating that the
new MVAs induced changes either in the innate immune response of the host or in the key signaling
pathway on which the selected gene was acting.
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The primary adaptive immune response to most pathogens and vaccines is initiated in regional
LNs draining peripheral sites of antigen exposure [59]. But surprisingly, none of those previous studies
analyzed the innate responses that occur in draining LNs to the site of immunization. Those studies
analyzed innate responses in vitro, employing human or murine macrophage cell-lines [60], or primary
human monocytes [61]. Moreover, in one recent paper, which analyzed the in vivo innate responses
against MVA, serum cytokines were analyzed after intravenous inoculation, which is not a usual
immunization route [62]. Even more, many other studies related with deleted MVAs [18,22,33,34]
did not perform any assay to characterize the innate response induced by the deleted vector.
The results from our experiments demonstrated that at short times post-immunization (4 to 30 hpi)
MVA∆C12L/∆A44L-A46R induced higher levels of cytokines with a determining role in the generation
of T-cell immune responses such as IL-12 and IFN-γ [63–65]. Even more, MVA∆C12L/∆A44L-A46R
also induced higher levels of IL-1β, a cytokine with reported effects to enhance CD4+ T-cells [66], and
antigen-specific CD8+ T-cell responses [67]. In addition, higher levels of IFN-β mRNA were induced by
the MVA∆C12L/∆A44L-A46R. This antiviral cytokine is also considered as an important “third signal”
with capacity to shape effector and memory T-cell pools [68]. Indeed, previous studies demonstrated
that production of type I IFN played a pivotal role in innate and adaptive immune responses to VACV
infection [69] and also that IFN-β can promote the expansion of MVA-induced CD8+ T cells [70].
5. Conclusions
This study describes for the first time that simultaneous deletion from the MVA-backbone of VACV
genes A44L, A46R and C12L (MVA∆C12L/∆A44L-A46R) was translated into a significant enhancement
of CD4+ and CD8+ T-cell adaptive responses, and importantly major quality T-cell characteristics were
improved. Absence of the biological functions of the deleted genes was demonstrated by specific
assays, and after in vivo experiments we found that the deletion of the selected genes from MVA
genome generated an innate response in the regional LNs to the site of immunization characterized by
an increase in IFN-γ, IL-12, and also IL-1β and IFN-β.
Supplementary Materials: The following are available online www.mdpi.com/1999-4915/8/5/139/s1, Figure S1:
In vitro characterization of MVA∆A44L-A46R and MVA∆C12L/∆A44L-A46R, Figure S2: Quantification of IgG,
IgG1 and IgG2a levels in serum from immunized mice.
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ICS Intracellular cytokine staining
MVA Modified Vaccinia Ankara Virus
moi multiplicity of infection
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SPF specific pathogen free
TCM T-cell Central Memory
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